Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 491 to 500 of 2440 total matches.
Trifarotene (Aklief) - A New Topical Retinoid for Acne
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019 (Issue 1587)
by
prescription for decades. Adapalene 0.1% gel has been
available over the counter since 2016 for treatment ...
The FDA has approved trifarotene 0.005% cream
(Aklief – Galderma) for topical treatment of acne
vulgaris in patients ≥9 years old. Trifarotene is the
fourth topical retinoid to be approved in the US for
treatment of acne; tretinoin (Retin-A, and others),
adapalene (Differin, and generics), and tazarotene
(Tazorac, and others) have been available by
prescription for decades. Adapalene 0.1% gel has been
available over the counter since 2016 for treatment of
acne in patients ≥12 years old.
Letermovir (Prevymis) for CMV Prophylaxis
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019 (Issue 1587)
.
Pronunciation Key
Letermovir: le term’ oh veer Prevymis: preh’ vih miss
Table 1. Pharmacology
Class CMV DNA ...
The FDA has approved letermovir (Prevymis – Merck),
a cytomegalovirus (CMV) DNA terminase complex
inhibitor, for prophylaxis of CMV infection and disease
in CMV-seropositive adult recipients of an allogeneic
hematopoietic cell transplant (HCT). Letermovir is
the first CMV DNA terminase complex inhibitor to
be approved in the US and the only drug specifically
indicated for CMV prophylaxis in HCT patients. It is not
approved for treatment of CMV infection.
Annovera - A New Contraceptive Vaginal Ring
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019 (Issue 1587)
etonogestrel and ethinyl estradiol, was the
first.1 Unlike NuvaRing, which requires use of a new
ring each ...
Annovera (TherapeuticsMD), a contraceptive vaginal
ring that releases segesterone acetate, a synthetic
progestin, and ethinyl estradiol, was approved by the
FDA in 2018 and is now available. It is the first product
to contain segesterone and the second vaginal ring
to become available in the US; NuvaRing, which
delivers etonogestrel and ethinyl estradiol, was the
first. Unlike NuvaRing, which requires use of a new
ring each month, the Annovera ring can be used for
an entire year, but it must be removed for one week
each month.
Darolutamide (Nubeqa) for Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019 (Issue 1587)
inhibitor to be approved for this
indication; apalutamide (Erleada)1 and enzalutamide
(Xtandi),2 which ...
The FDA has approved darolutamide (Nubeqa –
Bayer), an androgen receptor inhibitor, for oral
treatment of nonmetastatic castration-resistant
prostate cancer (nmCRPC). Darolutamide is the third
androgen receptor inhibitor to be approved for this
indication; apalutamide (Erleada) and enzalutamide
(Xtandi), which are also approved for use in patients
with metastatic castration-resistant prostate cancer
(mCRPC), were approved earlier.
Drugs for Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • Dec 02, 2019 (Issue 1586)
is reviewed in a separate issue.1
In general, all eye drops should be given in doses of one
drop ...
This issue includes reviews of drugs for glaucoma,
age-related macular degeneration (AMD), bacterial
conjunctivitis, and dry eye disease. Allergic conjunctivitis
is reviewed in a separate issue.
Turmeric Supplements
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019 (Issue 1585)
varies. Premium Turmeric
1,000 mg capsules (TruNature) is the only USP-verifi ed
turmeric product ...
Turmeric is a spice derived from the Curcuma longa
plant. Dietary supplements and foods containing
turmeric are widely promoted for relief of pain
and to improve joint mobility, immunity, digestion,
cardiovascular health, depression, anxiety, memory,
and cognition.
Upadacitinib (Rinvoq) - A New JAK Inhibitor for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019 (Issue 1585)
Upadacitinib (Rinvoq) — A New JAK
Inhibitor for Rheumatoid Arthritis
Table 1. Pharmacology
Class ...
The FDA has approved upadacitinib (Rinvoq –
Abbvie), an oral Janus kinase (JAK) inhibitor, for
treatment of adults with moderately to severely
active rheumatoid arthritis (RA) who have had
an inadequate response to or cannot tolerate
methotrexate (Trexall, and others). Upadacitinib is
the third JAK inhibitor to be approved in the US for
treatment of RA; tofacitinib (Xeljanz, Xeljanz XR)
and baricitinib (Olumiant) were approved earlier.
Cannabis and Cannabinoids
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019 (Issue 1585)
psychoactive
constituent of cannabis. CBD, unlike THC, does not
produce intoxication or euphoria.1,2
THC ...
Cannabis (marijuana) contains more than 60
pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
are the best known. THC is the main psychoactive
constituent of cannabis. CBD, unlike THC, does not
produce intoxication or euphoria.
In Brief: A New Glucagon Injection (Gvoke) for Severe Hypoglycemia
The Medical Letter on Drugs and Therapeutics • Nov 18, 2019 (Issue 1585)
for use in patients ≥4 years old.1
Children ...
The FDA has approved a new formulation of glucagon
(Gvoke – Xeris) for subcutaneous treatment of severe
hypoglycemia in patients ≥2 years old with diabetes.
Conscious patients with symptoms of hypoglycemia can
take oral glucose. Glucagon is usually administered by a
caregiver to an unresponsive patient. The new formulation is
available in a single-use prefilled syringe (Gvoke PFS) and is
expected to become available in a single-use auto-injector
(Gvoke HypoPen) in 2020. Unlike previously available
injectable glucagon products (Glucagon Emergency Kit,
and others), Gvoke does not...
Oral Semaglutide (Rybelsus) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Oct 21, 2019 (Issue 1583)
-1
(GLP-1) receptor agonist semaglutide (Rybelsus –
Novo Nordisk) has been approved by the FDA ...
An oral formulation of the glucagon-like peptide-1
(GLP-1) receptor agonist semaglutide (Rybelsus –
Novo Nordisk) has been approved by the FDA
for once-daily treatment of type 2 diabetes in
adults. Semaglutide, which has been available in
a subcutaneously-injected formulation (Ozempic)
since 2017, is the first GLP-1 receptor agonist to
become available for oral administration; the 4 other
GLP-1 receptor agonists currently available in the US
are administered by subcutaneous (SC) injection.